Francis Chris has demonstrated a clear selling bias in recent transactions involving Wave Life Sciences (WVE), with no recorded buys in the latest filings. Over 31 reported trades, Chris has sold approximately $7.1 million worth of WVE shares while purchasing $2.28 million, reflecting a net divestment trend. The most significant activity occurred on December 8, 2025, when Chris executed multiple sales totaling over $4.3 million, including a single transaction valued at $1.74 million. Smaller but consistent sales followed in early 2026, including a $270,182 disposal on February 26, 2026, and a $229,410 sale the same day.
The transactions also included multiple "M"-coded (market) and "S"-coded (sale) filings, with occasional "A"-coded (award) entries showing no monetary value. Notably, all recent activity has been concentrated in WVE, with no diversification across other securities. The absence of recent buys, coupled with the frequency and scale of sales—particularly the December 2025 cluster—suggests a sustained reduction in Chris’s position in the company. The pattern aligns with a broader disposition strategy, though the filings do not indicate whether the sales were part of prearranged trading plans or discretionary decisions.
AI-assisted summary